Products for Research Use Only

LMK-235

CAT: 0804-HY-18998-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18998-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC50s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.
CAS Number
1418033-25-6
UNSPSC
12352005
Hazard Statement
H302
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LMK-235.html
Purity
99.61
Solubility
DMSO : 175 mg/mL (ultrasonic)
Smiles
O=C(NOCCCCCC(NO)=O)C1=CC(C)=CC(C)=C1
Molecular Formula
C15H22N2O4
Molecular Weight
294.35
Precautions
H302
References & Citations
[1]Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56 (2) :427-36.|[2]Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7 (25) :37966-37978.|[3]Trazzi S, et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet. 2016 Sep 15;25 (18) :3887-3907.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC11; HDAC2; HDAC4; HDAC5; HDAC6; HDAC8

Alternative Products